Trade Jazz Pharmaceuticals plc - JAZZ CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.22 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 103.31 |
| Open | 104.94 |
| 1-Year Change | -3.55% |
| Day's Range | 103.66 - 106.37 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2025 | 104.03 | -0.82 | -0.78% | 104.85 | 106.38 | 103.38 |
| Apr 22, 2025 | 103.31 | 2.31 | 2.29% | 101.00 | 103.58 | 100.48 |
| Apr 21, 2025 | 100.21 | -1.79 | -1.75% | 102.00 | 102.00 | 98.77 |
| Apr 17, 2025 | 102.55 | 1.80 | 1.79% | 100.75 | 104.37 | 100.00 |
| Apr 16, 2025 | 101.08 | -1.46 | -1.42% | 102.54 | 103.45 | 100.02 |
| Apr 15, 2025 | 102.42 | 1.23 | 1.22% | 101.19 | 103.85 | 100.53 |
| Apr 14, 2025 | 101.21 | -0.87 | -0.85% | 102.08 | 102.90 | 99.97 |
| Apr 11, 2025 | 100.30 | 0.35 | 0.35% | 99.95 | 101.74 | 98.42 |
| Apr 10, 2025 | 101.46 | -6.04 | -5.62% | 107.50 | 107.50 | 96.10 |
| Apr 9, 2025 | 109.21 | 8.16 | 8.08% | 101.05 | 110.37 | 95.21 |
| Apr 8, 2025 | 102.38 | -7.99 | -7.24% | 110.37 | 110.37 | 101.18 |
| Apr 7, 2025 | 106.35 | 1.73 | 1.65% | 104.62 | 111.17 | 103.93 |
| Apr 4, 2025 | 109.92 | -5.82 | -5.03% | 115.74 | 115.99 | 109.15 |
| Apr 3, 2025 | 120.37 | -3.30 | -2.67% | 123.67 | 124.70 | 119.66 |
| Apr 2, 2025 | 125.93 | 2.03 | 1.64% | 123.90 | 127.62 | 123.90 |
| Apr 1, 2025 | 124.63 | 1.13 | 0.91% | 123.50 | 127.22 | 122.27 |
| Mar 31, 2025 | 124.02 | 3.01 | 2.49% | 121.01 | 124.51 | 119.83 |
| Mar 28, 2025 | 122.38 | -2.74 | -2.19% | 125.12 | 125.78 | 122.31 |
| Mar 27, 2025 | 125.82 | -4.13 | -3.18% | 129.95 | 130.20 | 125.77 |
| Mar 26, 2025 | 130.75 | -3.26 | -2.43% | 134.01 | 134.55 | 127.51 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Jazz Pharma Company profile
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Jazz Pharmaceuticals PLC revenues increased 31% to $3.09B. Net loss totaled $329.7M vs. income of $238.6M. Revenues reflect Sunosi segment increase from $28.3M to $2.34B, Zepzelca segment increase from $90.4M to $246.8M, United States segment increase of 32% to $2.82B, Europe segment increase of 31% to $230.2M. Net loss reflects Selling.
Equity composition
Common Stock $.0001 Par, 4/11, 150M auth., 40,741,809 issd. Insiders & stakeholders own 2.30%. IPO 6/1/07, 6M shares @ $18 per share by Morgan Stanley & Co. Incorporated, Lehman Brothers Inc. 5/07 Reverse stock split 1 for 11.06701. PO: 7/08, 3.8M shares.
| Industry: | Pharmaceuticals (NEC) |
Fifth Fl
Waterloo Exchange
DUBLIN
DUBLIN 4
IE
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com